Research programme: anti-cancer therapeutics - OncoRx Pharmaceuticals

Drug Profile

Research programme: anti-cancer therapeutics - OncoRx Pharmaceuticals

Alternative Names: ORX 101; ORX 102; ORX 103; Tumour-activated nanodrug programme - OncoRx

Latest Information Update: 05 Dec 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Unknown
  • Developer OncoRx Pharmaceuticals Inc
  • Class Antineoplastics; Phenothiazines; Small molecules
  • Mechanism of Action Apoptosis stimulants; Integrin alpha4beta1 modulators; P-glycoprotein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Cancer

Highest Development Phases

  • Research Cancer

Most Recent Events

  • 02 Dec 2015 OncoRx Pharmaceuticals has patent protection for its drugs for the treatment of therapy-resistant malignant tumours in USA
  • 19 Oct 2015 OncoRx Pharmaceuticals plans preclinical trials for Glioma and glioblastoma
  • 23 Sep 2015 Research programme: anti-cancer therapeutics - OncoRx Pharmaceuticals is available for licensing in World as of 19 Oct 2015. www.oncorxpharmaceuticalscom
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top